Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis

  • Authors:
    • Binhong Wen
    • Lu Zhao
    • Hongmei Zhao
    • Xiaochen Wang
  • View Affiliations

  • Published online on: April 10, 2018     https://doi.org/10.3892/etm.2018.6043
  • Pages: 5077-5083
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liraglutide, a glucagon‑like peptide‑1 receptor agonist, is an anti‑diabetic medicine associated with a reduced risk of fracture in diabetic patients. In the present study, rats with streptozotocin (STZ)‑induced diabetes and/or bilateral ovariectomy (OVX) were treated with liraglutide for eight weeks. Liraglutide treatment increased insulin secretion and managed blood glucose levels in the rats following STZ‑induced diabetes. In addition, STZ‑ and OVX‑induced reduction of femoral bone mineral density and destruction of bone microarchitecture were alleviated by liraglutide. STZ decreased, whereas OVX increased, serum osteocalcin (OC) level (a bone formation marker) and osteoblast counts in the trabecular bone. OVX, however not STZ, markedly increased the level of serum c‑terminal telopeptide of type 1 collagen (CTX‑1, a bone resorption marker) and osteoclast counts in the trabecular area. Liraglutide treatment significantly increased serum OC levels in all three osteoporotic models, however had minimal effects on osteoblast counts. Furthermore, liraglutide significantly decreased serum CTX‑1 level and osteoclast numbers in OVX and STZ+OVX rats. Furthermore, the present study examined the mRNA expression and serum concentrations of osteoprotegerin (OPG) and receptor activator of nuclear factor‑κB ligand (RANKL), and liraglutide significantly decreased the RANKL/OPG ratio compared with the untreated rats, indicating that osteoclastogenesis was inhibited by liraglutide. In summary, the results suggested that liraglutide ameliorates STZ+OVX‑induced bone deterioration in the rat model, primarily through the inhibition of osteoclastogenesis. These preliminary findings propose a potentially beneficial effect of liraglutide on the bone health of postmenopausal diabetic patients.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wen B, Zhao L, Zhao H and Wang X: Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med 15: 5077-5083, 2018.
APA
Wen, B., Zhao, L., Zhao, H., & Wang, X. (2018). Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis. Experimental and Therapeutic Medicine, 15, 5077-5083. https://doi.org/10.3892/etm.2018.6043
MLA
Wen, B., Zhao, L., Zhao, H., Wang, X."Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis". Experimental and Therapeutic Medicine 15.6 (2018): 5077-5083.
Chicago
Wen, B., Zhao, L., Zhao, H., Wang, X."Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis". Experimental and Therapeutic Medicine 15, no. 6 (2018): 5077-5083. https://doi.org/10.3892/etm.2018.6043